Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Retroviruses ensure that their reverse-transcribed RNA genomes are integrated into the DNA of host cells, a characteristic that has prompted their use as gene-therapy vectors. In a Perspective, Trono discusses new findings (Wu et al.) that describe how two retroviruses, MLV and HIV, show very different sites of integration in the human genome. Trono explains the important implications of these findings for the use of retroviral vectors in gene therapy.
The author is in the Department of Genetics and Microbiology, University of Geneva, Switzerland. E-mail: didier.trono{at}medecine.unige.ch
Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells.
T. VandenDriessche, Z. Ivics, Z. Izsvak, and M. K. L. Chuah (2009)
Blood
114, 1461-1468
|Abstract »|Full Text »|PDF »
Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells.
F. Zhang, S. I. Thornhill, S. J. Howe, M. Ulaganathan, A. Schambach, J. Sinclair, C. Kinnon, H. B. Gaspar, M. Antoniou, and A. J. Thrasher (2007)
Blood
110, 1448-1457
|Abstract »|Full Text »|PDF »
Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells.
M. De Palma, E. Montini, F. R. S. de Sio, F. Benedicenti, A. Gentile, E. Medico, and L. Naldini (2005)
Blood
105, 2307-2315
|Abstract »|Full Text »|PDF »
